OSMOLEX ER (amantadine hydrochloride) by Supernus Pharmaceuticals is clinical pharmacology pharmacodynamics mechanism of action antiviral the mechanism by which amantadine exerts its antiviral activity is not clearly understood. First approved in 2018.
Drug data last refreshed 29m ago · AI intelligence enriched 1w ago
OSMOLEX ER is an extended-release oral formulation of amantadine hydrochloride, a small-molecule antiviral and dopaminergic agent approved in 2018. It treats influenza A virus infections and Parkinson's disease symptoms by inhibiting viral M2 protein function and modulating NMDA receptors and dopamine neurotransmission, respectively. The mechanism in Parkinson's disease remains incompletely understood but involves weak NMDA antagonism and indirect dopaminergic effects.
Product is at peak lifecycle stage with modest Part D penetration (~$2M in 2023 spending), suggesting stable but niche commercial positioning for a mature therapeutic class.
CLINICAL PHARMACOLOGY Pharmacodynamics Mechanism of Action Antiviral The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the…
Worked on OSMOLEX ER at Supernus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moOSMOLEX ER careers are concentrated in commercial and market access functions, supporting a niche, mature therapeutic product at peak lifecycle. Roles typically involve defending market share against generics, optimizing formulary access, and preparing for eventual LOE transition rather than pursuing expansion growth.